Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Stock Information for Oncolytics Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncolytics Biotech Inc.

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
High?Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.